NOTVQ (Inotiv) Total Liabilities: $625.3 Mil (As of Mar. 2026)


What is Inotiv Total Liabilities?

Inotiv NOTVQ -9.91% Total Liabilities is $625.3 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

Inotiv's Total Liabilities for the quarter that ended in Mar. 2026 was $625.3 Mil.

Inotiv's quarterly Total Liabilities declined from Sep. 2025 ($635.09 Mil) to Dec. 2025 ($625.31 Mil) but then increased from Dec. 2025 ($625.31 Mil) to Mar. 2026 ($625.32 Mil).

Inotiv's annual Total Liabilities increased from Sep. 2023 ($588.04 Mil) to Sep. 2024 ($610.86 Mil) and increased from Sep. 2024 ($610.86 Mil) to Sep. 2025 ($635.09 Mil).

Inotiv Total Liabilities Historical Data

* Premium members only.

The historical data trend for Inotiv's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inotiv Total Liabilities Chart

Inotiv Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 216.73 603.13 588.04 610.86 635.09

Inotiv Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 608.27 615.95 635.09 625.31 625.32

Inotiv Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Inotiv's Total Liabilities for the fiscal year that ended in Sep. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=556.784+(46.774+13.29
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+18.238+0+0)
=635.1

Total Liabilities=Total Assets (A: Sep. 2025 )-Total Equity (A: Sep. 2025 )
=771.114-136.028
=635.1

Inotiv's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=540.285+(57.301+13.612
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+14.121+0+0)
=625.3

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=702.418-77.099
=625.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $625.3 Mil mean?
Inotiv (NOTVQ) has a Total Liabilities of $625.3 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Inotiv and its competitors.
Is Inotiv's Total Liabilities too high?
Inotiv's current Total Liabilities is $625.3 Mil.
How does Inotiv's Total Liabilities compare to NDRA and XWEL?
Inotiv's Total Liabilities of $625.3 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Diagnostics & Research company?
A good Total Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Inotiv and its competitors. Inotiv's current Total Liabilities is $625.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inotiv stock overvalued right now?
Based on GuruFocus' analysis, Inotiv (NOTVQ) is currently considered Possible Value Trap. The stock's GF Value™ is $1.68, compared to a current price of $0.01 — trading 99.4% below its estimated fair value. The current Total Liabilities is $625.3 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Inotiv (NOTVQ), the current Total Liabilities is $625.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inotiv Business Description

Other Exchanges BS50:Germany
Address 2701 Kent Avenue, West Lafayette, IN, USA, 47906
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.